# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic rang...
HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...
- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid ...
- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid ...
HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...
Promising early data suggest patients with relapsed/refractory multiple myeloma who progressed after prior BCMA-targeted therap...